Approval for golimumab (which will by marketed under the trade name Simponi) was granted this week by the U.S. Food and Drug Administration. The drug received approval for the treatment of moderate to severe RA (in conjunction with methotrexate), active psoriatic arthritis (as monotherapy or with methotrexate), and active ankylosing spondylitis at a dose of 50 mg injected monthly for all three conditions. The drug, a humanized monoclonal antibody that neutralizes TNF-α, is the fourth TNF inhibitor approved to treat these conditions and the third that is self-injected. As with the other approved TNF inhibitors, the FDA has included a black box warning regarding the potential for reactivation of tuberculosis and invasive fungal infections. Summaries of golimumab publications and scientific abstracts for the treatment of RA previously included on this website are available to review.
A Small Favor
More than 15 years ago the Arthritis Center launched this website with the mission to bring current and accurate disease education to health care professionals and patients alike. Content on our site is generated directly by our team members. Unlike many health education websites we do not accept advertising, paid guests posts or charge for access to our site.
That’s where you come in. Your support will allow us to continue to deliver this valuable information to over 1 million visitors each year.Contribute TodayMore Ways to Give